Search
for
Did you mean Dipeptidyl Peptidase-4 Inhibitors?
Learn
5 / 801 resultslearn multipeptides
learn Gluco peptide
learn octapeptide-2
learn DECAPEPTIDE-28
Research
5 / 268 results
research Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
Medications for PCOS don't seem to raise heart disease risk.
research Alopecia areata universalis nach Sitagliptin-Einnahme
A patient's hair loss may be linked to their diabetes medication, Sitagliptin.
research Inhibiting dipeptidyl peptidase 4 positive fibroblasts using zinc sulfide cellulose nanofiber scaffolds to achieve scarless healing
Zinc sulfide cellulose scaffolds can reduce scarring and promote hair growth.
research Linagliptin-Associated Alopecia and Bullous Pemphigoid
Linagliptin may cause hair loss and skin blisters.
research Repurposing DPP4-Inhibition to Improve Hair Follicle Activation and Regeneration
Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.
Community Join
5 / 1000+ resultscommunity Does anyone know of the actual effectiveness of the DP2 inhibitors?
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community Peptide Therapy -> GHK-CU, ZN-Thumulin, PTD-DBM
The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.
community Upcoming Setipiprant clinical trials hint at systemic daily dosage
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.